VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
MELBOURNE, Australia, Aug. 4 /PRNewswire-FirstCall/ -- starpharma
Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced the results of its clinical trial demonstrating that VivaGel(R) retains antiviral activity a...
Starpharma and Elanco Sign Agreement
... MELBOURNE, Australia, May 11 /PRNewswire/ -- starpharma
Holdings Limited (ASX:SPL, OTCQX:SPHRY) today anno...harma's dendrimer technology. Under the agreement, starpharma
will receive revenue from research fees, and is el...otential applications of its dendrimer technology. starpharma
also has partnerships with SSL International (Dure...
FDA Warning for N-9 - an Opportunity for VivaGel(R)
...selves from infection with these serious diseases. starpharma
on developing VivaGel(R), both as a stan...HRMS/DOCKETS/98fr/07-6111.htm About Starpharma
Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world...s principally composed of two
operating companies, starpharma
Pty Ltd in Melbourne, Australia and
Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
Undisclosed fees are payable to starpharma
under the co-development
agreement, which also pro...l position and the strength of the
Durex(R) brand, starpharma
also values the organisation's innovative
unrelated condom coating agreements signed by starpharma
in the last three
months," concluded Dr. Fairley. ...
Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission
... The pharmaceutical company starpharma
saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent transmission of HIV. // The company...
UCSF study will test new vaginal microbicide for herpes and HIV
... If she were a sex worker it could be several times a day," she said.
The study is being conducted in collaboration with the gel’s manufacturer, starpharma
Holdings, Ltd., of Melbourne, Australia, and is being underwritten by the Sexually Transmitted Infection Clinical Trials Group, which is funded in par...
World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
...armaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc., starpharma
Holdings Limited, and Wyeth Pharmaceuticals Inc., among others.
The report titled "Nanomedicine: A Global Strategic Business Report" ann...